ATC Code: G02CB01, N04BC01.
Adults and Pediatrics (aged 7-17 years): The safety and effectiveness of bromocriptine in pediatric patients has only been established for the Prolactinomas and Acromegaly indications, in pediatrics aged 7-17 years.
Prolactinomas: Conservative treatment of prolactin-secreting pituitary micro- or macro-adenomas.
Prior to surgery in order to reduce tumour size and to facilitate removal.
After surgery if prolactin level is still elevated.
Acromegaly: As an adjunct, or in special cases as an alternative, to surgery or radiotherapy.
Adults: Parkinson's disease: All stages of idiopathic and postencephalitic Parkinson's disease, either as monotherapy or in combination with other antiparkinsonian drugs.
Hyperprolactinaemia in men: Prolactin-related hypogonadism: anovulatory cycles (supplementary to anti-estrogens, e.g. clomiphene).
Adult: Parkinsonism as dopamine agonist: start with a low dose of 1.25 mg (½ tablet) per day, given preferably in the evening, for the first week.
Prolactinomas: 1.25 mg (½ tablet) 2 or 3 times daily, gradually increasing to several tablets daily as required to keep plasma prolactin adequately suppressed.
Acromegaly: Initially 1.25 mg (½ tablet) 2 or 3 times daily, gradually increasing to 10 to 20 mg daily, depending on clinical response and side effects.
Hyperprolactinaemia in men: 1.25 mg (½ tablet) 2 or 3 times daily, gradually increasing to 5 to 10 mg per day.
Pediatrics (aged 7-17 years): Prolactinomas: Pediatric population older than 7 years: 1.25 mg (½ tablet) 2 or 3 times daily, gradually increasing to several tablets daily as required to keep plasma prolactin adequately suppressed. Maximum daily dose recommended in children aged 7 to 12 years is 5 mg. Maximum daily dose recommended in adolescent patients (13-17 years) is 20 mg.
Acromegaly: Pediatric population older than 7 years: Initially 1.25 mg (½ tablet) 2 or 3 times daily, gradually increasing to several tablets daily, depending on clinical response and side effects. Maximum daily dose recommended in children aged 7 to 12 years is 10 mg. Maximum daily dose recommended in adolescent patients (13-17 years) is 20 mg.
Renal impairment: No studies have been performed in renally impaired patients.
Hepatic impairment: No studies have been performed in hepatically impaired patients.
Use in the Elderly (aged 65 years and above): Even though no variation in efficacy or adverse reaction profile in elderly patients taking Parlodel has been observed, greater sensitivity in some elderly individuals cannot be ruled out. In general, dose selection for an elderly patient should be cautious, starting at the lower end of the dose range, reflecting the greater frequency of decreased hepatic, renal or cardiac function, and of concomitant disease or other drug therapy in this population.
Common: nasal congestion, somnolence,
headache, dizziness, nausea, constipation, vomiting.
CYP 3A4 substrates/inhibitors: Bromocriptine is both a substrate and an inhibitor of CYP3A4. Caution should therefore be used when co-administering drugs which are strong inhibitors and/or substrates of this enzyme (azole antimycotics, HIV protease). The concomitant use of macrolide antibiotics such as erythromycin or josamycin, was shown to increase the plasma levels of bromocriptine. The concomitant treatment of acromegalic patients with bromocriptine and octreotide led to increased plasma levels of bromocriptine.
Sympathomimetic drugs: Co-administration of sympathomimetics such as phenylpropanolamine and bromocriptine may lead to hypertension and severe headache.
Sumatriptan: Co-administration of sumatriptan may potentiate the risk of vasospastic reactions due to additive pharmacological effects.
Ergot alkaloids: Co-administration may increase the dopamine stimulant activity and lead to dopaminergic side effects such as headache, nausea, vomiting.
Dopamine receptor antagonists: dopamine antagonists such as antipsychotics (phenothiazines, butyrophenones & thioxanthenes), but also metoclopramide and domperidone may reduce its activity.
Alcohol: The tolerability to Parlodel may be reduced by alcohol.
N04BC01 - bromocriptine ; Belongs to the class of dopamine agonist. Used in the management of Parkinson's disease.
Parlodel tab 2.5 mg
10 × 10's
Sign Out
